FIDA offers a new proprietary technology developed for quantification and characterization of proteins (including biologics), early detection of immune responses (including immunogenicity testing) and affinity assessment. FIDA is characterized by being fast (minutes), requiring very small sample amounts (nL-mL), and being exceptionally tolerant to the sample matrix. Contrary to most other procedures, the FIDA methodology is based on binding in homogenous solution; complications related to non-specific surface adsorption and challenging assay development is therefore avoided. The unique features of FIDA enable characterization and quantification in native (biorelevant) environments and in-built assay quality control and automation.
| Website | http://www.fida-tech.com |
| Employees | 23 (23 on RocketReach) |
| Founded | 2013 |
| Industry | Biotechnology, Drug Discovery |
| Keywords | Protein Quantification, Protein Characterization, Early Disease Detection, Assay Development, Biopharmaceutical Analysis, Therapeutic Proteins, Molecular Diagnostics, Protein Analysis, Biomarker Discovery, Immunology Research, Protein Engineering, Drug Development, Pharmaceutical Research, Biotechnology, Life Sciences |
Looking for a particular FIDA-Tech employee's phone or email?
Niels Bau-Madsen is the CTO of FIDA-Tech.
23 people are employed at FIDA-Tech.
FIDA-Tech is based in Copenhagen, Capital Region.